Department of Pediatrics, Roswell Park Cancer Institute, University at Buffalo, Buffalo, NY, USA.
Future Oncol. 2013 Dec;9(12):1829-39. doi: 10.2217/fon.13.219.
Ofatumumab is a fully human, IgG anti-CD20 monoclonal antibody codeveloped by GlaxoSmithKline (Brentford, UK) and Genmab (Copenhagen, Denmark). In preclinical studies, ofatumumab exhibited more potent in vitro activity than rituximab against B-cell malignancies and prolonged survival in in vivo animal models compared with rituximab. Ofatumumab is clinically well tolerated with initial infusion reactions being the predominant associated toxicity. Ofatumumab has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and has received regulatory approval in both Europe and the USA for treatment of fludarabine and alemtuzumab refractory disease. Single-agent ofatumumab has resulted in overall response rates of 42-51% in relapsed/refractory CLL and up to 80% when combined with chemotherapy. In de novo CLL, overall response rates of 77-78% have been achieved.
奥法妥木单抗是一种完全人源化 IgG1 抗 CD20 单克隆抗体，由葛兰素史克（英国布伦特福德）和 Genmab（丹麦哥本哈根）联合开发。在临床前研究中，与利妥昔单抗相比，奥法妥木单抗对 B 细胞恶性肿瘤具有更强的体外活性，并在体内动物模型中延长了生存时间。与利妥昔单抗相比，奥法妥木单抗具有良好的临床耐受性，最初的输注反应是主要相关毒性。奥法妥木单抗在复发/难治性慢性淋巴细胞白血病（CLL）中显示出疗效，并已在欧洲和美国获得批准，用于治疗氟达拉滨和阿仑单抗难治性疾病。单药奥法妥木单抗在复发/难治性 CLL 中的总缓解率为 42-51%，与化疗联合使用时可达到 80%。在初治 CLL 中，总缓解率达到 77-78%。
Zotero 插件